Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Venrock Healthcare Capital Par Buys 88,794 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $11.44 per share, with a total value of $1,015,803.36. Following the acquisition, the insider now directly owns 4,148,428 shares of the company’s stock, valued at $47,458,016.32. This represents a 2.19 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par acquired 8,971 shares of Oruka Therapeutics stock. The shares were acquired at an average cost of $11.86 per share, with a total value of $106,396.06.
• On Monday, February 10th, Venrock Healthcare Capital Par acquired 574 shares of Oruka Therapeutics stock. The shares were acquired at an average cost of $10.90 per share, with a total value of $6,256.60.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $10.15 on Friday. The stock has a market capitalization of $355.24 million, a price-to-earnings ratio of -1.62 and a beta of 0.77. Oruka Therapeutics, Inc. has a fifty-two week low of $9.53 and a fifty-two week high of $53.88. The company’s 50 day moving average is $14.29.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. purchased a new stake in shares of Oruka Therapeutics during the fourth quarter valued at approximately $6,787,000. Toronto Dominion Bank purchased a new stake in Oruka Therapeutics in the fourth quarter worth $1,131,000. Frazier Life Sciences Management L.P. lifted its stake in Oruka Therapeutics by 22.2% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 583,327 shares of the company’s stock worth $11,311,000 after acquiring an additional 106,000 shares during the period. VR Adviser LLC lifted its stake in Oruka Therapeutics by 6.5% in the fourth quarter. VR Adviser LLC now owns 3,285,620 shares of the company’s stock worth $63,708,000 after acquiring an additional 200,000 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in Oruka Therapeutics in the fourth quarter worth $236,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, February 7th. Finally, Wolfe Research assumed coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.